News >

Novel Agents Show Enhanced Efficacy Across CLL Subtypes

Caroline Seymour
Published: Friday, Apr 19, 2019

Matthew S. Davids, MD

Matthew S. Davids, MD, MMSc
​​​​​​The introduction of novel agents such as ibrutinib (Imbruvica), idelalisib (Zydelig), venetoclax (Venclexta), and duvelisib (Copiktra), though not curative, are showing potential for deep remissions both as monotherapy and in combination in patients with chronic lymphocytic leukemia (CLL), explained Matthew S. Davids, MD, MMSc.

“There have been several exciting advances,” said Davids, associate director, Center for Chronic Lymphocytic Leukemia, Dana-Farber Cancer Institute. “Over the last 5 years, we've had several different drugs approved, typically, as monotherapies. These are drugs like ibrutinib, idelalisib, and venetoclax. More recently, the excitement has surrounded some of the data with combining these drugs together.”

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Individualizing Treatment After Second-Line Therapy for Patients With mCRCAug 29, 20191.0
Community Practice Connections™: Immunotherapeutic Strategies with the Potential to Transform Treatment for Genitourinary CancersAug 29, 20191.0
Publication Bottom Border
Border Publication
x